AR095502A1 - Anticuerpos profármaco contra el inhibidor de la vía del factor tisular - Google Patents

Anticuerpos profármaco contra el inhibidor de la vía del factor tisular

Info

Publication number
AR095502A1
AR095502A1 ARP140101107A ARP140101107A AR095502A1 AR 095502 A1 AR095502 A1 AR 095502A1 AR P140101107 A ARP140101107 A AR P140101107A AR P140101107 A ARP140101107 A AR P140101107A AR 095502 A1 AR095502 A1 AR 095502A1
Authority
AR
Argentina
Prior art keywords
inhibitor
propharm
antibodies
antibodies against
prodrug
Prior art date
Application number
ARP140101107A
Other languages
English (en)
Inventor
Wang Zhuozhi
Murphy John
Hermiston Terry
Zhu Ying
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095502A1 publication Critical patent/AR095502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

La presente divulgación proporciona anticuerpos profármaco que se unen específicamente al inhibidor de la vía del factor tisular (TFPI) únicamente tras la exposición a proteasas de la cascada de coagulación. Los anticuerpos profármaco descritos son útiles para tratar trastornos hemorrágicos, tales como hemofilia. Cuando se usa en dichos tratamientos, estos anticuerpos profármaco muestran una mayor semivida respecto a otros anticuerpos anti-TFPI a la vez que mitigan el potencial de efectos secundarios tales como trombosis.
ARP140101107A 2013-03-15 2014-03-14 Anticuerpos profármaco contra el inhibidor de la vía del factor tisular AR095502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794024P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095502A1 true AR095502A1 (es) 2015-10-21

Family

ID=51537758

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101107A AR095502A1 (es) 2013-03-15 2014-03-14 Anticuerpos profármaco contra el inhibidor de la vía del factor tisular

Country Status (10)

Country Link
US (1) US20160009817A1 (es)
EP (1) EP2970498A4 (es)
JP (1) JP2016514687A (es)
CN (1) CN105209496A (es)
AR (1) AR095502A1 (es)
CA (1) CA2906095A1 (es)
HK (1) HK1215262A1 (es)
TW (1) TW201522368A (es)
UY (1) UY35459A (es)
WO (1) WO2014144689A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
SG10201710727UA (en) * 2013-05-28 2018-02-27 Dcb Usa Llc Antibody locker for the inactivation of protein drug
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
CN108289952B (zh) 2015-11-19 2021-02-05 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分***的功能性抗体片段互补作用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109641047A (zh) 2016-05-20 2019-04-16 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
WO2018107125A1 (en) 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
WO2018160754A2 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3619234A4 (en) * 2017-05-03 2021-05-26 Harpoon Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPIES
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELINE BINDING PROTEINS
KR20200040819A (ko) 2017-08-16 2020-04-20 브리스톨-마이어스 스큅 컴퍼니 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제
WO2019075378A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B-MATURATION ANTIGEN BINDING PROTEINS
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
CN113354715B (zh) * 2021-05-07 2023-03-17 暨南大学 Egfr的改造的结合蛋白及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
US9624309B2 (en) * 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
JP6035009B2 (ja) * 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
KR101745394B1 (ko) * 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
BRPI1006141B8 (pt) * 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
RU2580038C2 (ru) * 2009-12-04 2016-04-10 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
EP2536763A1 (en) * 2010-02-19 2012-12-26 Novo Nordisk A/S Activatable constructs
MY174760A (en) * 2010-03-01 2020-05-13 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
DK2547355T3 (en) * 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体

Also Published As

Publication number Publication date
CN105209496A (zh) 2015-12-30
HK1215262A1 (zh) 2016-08-19
JP2016514687A (ja) 2016-05-23
EP2970498A4 (en) 2016-11-23
US20160009817A1 (en) 2016-01-14
CA2906095A1 (en) 2014-09-18
WO2014144689A1 (en) 2014-09-18
UY35459A (es) 2014-10-31
TW201522368A (zh) 2015-06-16
EP2970498A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
AR095502A1 (es) Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CO2018001473A2 (es) Anticuerpos inhibidores de vía del factor tisular y usos de los mismos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
PE20160190A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
EA201690549A1 (ru) Арилэфиры и их применения
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
ECSP14030779A (es) Inhibidores del nampt
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
PE20160031A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y metodos de uso
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας
CO7121334A2 (es) Formulaciones vesiculares
EA201691057A1 (ru) Новые способы лечения нейродегенеративных заболеваний

Legal Events

Date Code Title Description
FB Suspension of granting procedure